Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

BACKGROUND: Eribulin mesylate is a nontaxane microtubule dynamics inhibitor approved for second-line (European Union) or third-line (United States) treatment of metastatic breast cancer. Two phase 2 single trials, evaluating first-line eribulin as monotherapy (Study 206; NCT01268150) or in combinati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Schwartzberg, Lee, McIntyre, Kristi, Wilks, Sharon, Puhalla, Shannon, O’Shaughnessy, Joyce, Berrak, Erhan, He, Yaohua, Vahdat, Linda
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567408/
https://ncbi.nlm.nih.gov/pubmed/31195996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5674-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky